Oncotarget

Research Papers:

Cancer stem cell markers predict a poor prognosis in renal cell carcinoma: a meta-analysis

Bo Cheng, Guosheng Yang _, Rui Jiang, Yong Cheng, Haifan Yang, Lijun Pei and Xiaofu Qiu

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:65862-65875. https://doi.org/10.18632/oncotarget.11672

Metrics: PDF 845 views  |   HTML 1015 views  |   ?  


Abstract

Bo Cheng1,2, Guosheng Yang2,3, Rui Jiang1, Yong Cheng1, Haifan Yang1, Lijun Pei1, Xiaofu Qiu2,3

1 Department of Urology, The Affiliated Hospital of Southwest Medical University, Luzhou 646000, China

2 Southern Medical University, Guangzhou 510280, China

3 Department of Urology, Guangdong No.2 Provincial People’s Hospital, Guangzhou 510317, China

Correspondence to:

Guosheng Yang, email: 2008yangguosheng@sina.com

Rui Jiang, email: jiangrui@126.com

Keywords: renal cancer, prognosis, cancer stem cells, biomarker, meta-analysis

Received: March 31, 2016    Accepted: August 10, 2016    Published: August 29, 2016

ABSTRACT

Background: Relevant markers of CSCs may serve as prognostic biomarkers of RCC. However, their actual prognostic significance remains inconclusive. Thus, a meta-analysis was performed to reevaluate the association of CSCs-relevant markers (CXCR4, CD133, CD44, CD105) expression with RCC prognosis more precisely.

Methods: PubMed and Embase were searched to look for eligible studies. The pooled hazard ratios (HR) with 95% confidence intervals (95% CI) were used to reassess the association of CSCs markers expression and RCC prognosis of overall survival (OS), cancer-specific survival (CSS), disease-free survival (DFS), and progression-free survival (PFS).

Results: There were 25 relevant articles, encompassing 2673 RCC patients, eligible for meta-analysis. Overall pooled analysis suggested that high CSCs markers expression predicted poor OS (HR, 2.10, 95% CI: 1.73–2.55) and DFS (HR, 3.77, 95% CI: 2.30–6.19). High CXCR4 expression predicted worse OS (HR, 2.57, 95% CI: 1.95–3.40), CSS (HR,1.97, 95% CI: 1.50–2.59), and DFS (HR, 5.82, 95% CI: 3.01–11.25). CD44 over-expression correlated with a poor OS(HR,1.58, 95% CI: 1.14–2.18), CSS (HR, 2.58, 95% CI: 1.27–5.23), and DFS (HR, 4.49, 95% CI: 2.12–9.53) in RCC patients. CD133 was an independent favorable prognostic factor for CSS (HR, 0.4, 95% CI: 0.29–0.54).

Conclusions: The presence of CSCs markers correlates with poor RCC outcome. CSCs may be potentially utilized as prognostic markers to stratify RCC patients, probably representing also a novel potential therapeutic target.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 11672